Double Blinded Drug Discovery (DBD2): A New Protected Open Innovation Model

2,777 views

|

August 22, 2012

Melvin Reichman, President & CEO, LIMR Chemical Genomics Center

Abstract
The Lankenau Chemical Genomics Center (LCGC) is a totally new, automated molecular diversity depot (patents issued and pending) offering university networks access to 'diversity-clustered smart-snapshots (DCSS) from big pharmas' vast chemical collections, under a symbiotically transformative, public-private consortium for drug discovery research.

Drug Discovery

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.